Status:
UNKNOWN
Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)
Lead Sponsor:
Scandinavia Pharma
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
Cross-sectional epidemiological study in patients with diagnosis of GERD (Gastroesophageal Reflux Disease) and with current treatment or with a history of recent treatment with some PPI (Proton Pump I...
Detailed Description
OBJECTIVE: To carry out an evaluation about the persistence and / or relapse of symptoms in Colombian patients with diagnosis of GERD. MATERIALS AND METHODS: A multicentric cross-sectional epidemiolo...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Previous diagnosis of Gastroesophageal Reflux Disease (GERD)
- CURRENT treatment with a proton-pump inhibitor (PPI), OR NOT CURRENT treatment with some PPI but YES in the last year
Exclusion
- Refusal to participate in the study by the patient.
- Patients who, in the judgment of the Investigator, do not understand or are not willing to adequately answer to the questions.
- Mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.
Key Trial Info
Start Date :
June 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04094402
Start Date
June 4 2019
End Date
July 1 2024
Last Update
September 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scandinavia Pharma
Bogotá, Colombia, 110111